
Hansa Biopharma’s imlifidase advances to Phase III testing
According to Lund-based Hansa Biopharma AB the study protocol has been greenlighted both by the FDA and the European Medicines Agency (EMA), so its...

Catalent swallows VMIC Ltd
The biologics development and manufacturing facility taken over from Vaccine Manufacturing and Innovation Centre UK Ltd. is locaterd n to the south...

Ellipses Pharma licences SRB22 from SunRock Biopharma
Under the agreement, British Ellipses Pharma Ltd has been granted global rights to develop and commercialise SBR22 (which it renamed to EP0017) from...

G7 heads call for decarbonisation of industry
The G7 ministers underlined the importance of efforts to improve energy efficiency, the need for increased investment in renewable energy, tracking...

French Ipsen falls after Epizyme take-over announcement
Even if Ipsen succeeds in halving the losses at Epizyme Inc, this would reduce the group's profit by nine percent by 2024, Credit Suisse analysts...

Single-use market to reach $20.8bn by 2026
The "Global Forecast 2026" comprises Media Bags and containers, Bioreactors, Mixers, Assemblies, Applications (Cell Culture, Mixing,...

$50m for London CHARM Therapeutics for deep minded folding expertise
London based CHARM Therapeutics rushes into the 3D deep-learning space with a $50M Series A financing co-led by F-Prime Capital and OrbiMed, with...